Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of SCH 417690 in treatment-naive HIV-1 infected subjects
2004-000390-59Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of vicriviroc in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Started Sep 2004; status: terminated.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-000390-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000390-59.